How AI Is Cutting Skin Cancer Waiting Times in Bradford

Bradford Teaching Hospitals NHS Foundation Trust is participating in an artificial intelligence project designed to support earlier skin cancer detection and improve the assessment of suspicious skin lesions. Reports link the project with shorter dermatology waiting times and fewer biopsies. Source 1 Source 3

The available reports do not identify the system’s manufacturer, algorithm, accuracy rate, regulatory status or precise clinical approval. They also do not establish that the technology independently diagnoses cancer.

How the AI May Be Used

An AI system of this type may analyse photographs or dermoscopic images, identify patterns associated with possible skin cancer and help clinicians prioritise referrals. It may flag higher-risk lesions, support image review and identify cases that require additional examination.

The technology is intended as clinical decision support, not as a replacement for dermatologists, specialist nurses, pathologists or other healthcare professionals. Clinicians must consider the patient’s symptoms, medical history, physical examination and changes in the lesion over time.

Bradford Teaching Hospitals NHS Foundation Trust’s participation in an AI project does not mean that every patient receives an automated diagnosis. Implementation may vary between clinics, referral routes and clinical teams. Source 3

How AI Could Shorten Waiting Times

AI may help dermatology teams review images more efficiently and prioritise cases according to apparent clinical risk. This could allow urgent cases to receive earlier attention while lower-risk cases move to routine review or monitoring.

Skin cancer care includes several potential waiting periods:

1. Referral to specialist contact.
2. Diagnostic assessment and image review.
3. Biopsy.
4. Pathology analysis.
5. Treatment.

The available reports do not specify which measure improved in Bradford. Faster assessment also depends on staffing, appointment availability, imaging capacity and pathology resources.

One report links the use of AI with fewer dermatology biopsies and shorter NHS waiting times. Source 9

Fewer unnecessary biopsies could reduce discomfort, scarring, bleeding, infection risk and pressure on pathology laboratories. However, the reduction must not result from avoiding clinically necessary biopsies. Some lesions require tissue testing even when their images appear relatively low risk.

Why Earlier Assessment Matters

NHS dermatology services manage large numbers of referrals, including suspected cancers and benign conditions. Delays can increase anxiety and place pressure on dermatologists, specialist nurses, imaging staff, pathologists and surgical teams.

Earlier assessment may provide faster reassurance for people with benign conditions and earlier escalation for suspicious lesions. However, the supplied sources do not provide Bradford-specific survival data or evidence that the project has improved long-term outcomes.

People should seek medical advice for a changing mole, a new lesion or a non-healing wound. Bleeding, persistent crusting, pain, or changes in size, shape or colour also require professional assessment. Patients should not rely on an automated screening tool when they have concerning symptoms.

The Role of Biopsies

A biopsy removes a tissue sample for laboratory examination. Pathologists use it to determine whether cancer is present and, when relevant, identify its type and features that guide treatment.

AI and imaging can provide valuable information, but they cannot replace tissue diagnosis in every case. Unusual lesions and some skin cancers may be difficult to identify from images alone.

The main safety risk is over-reliance on an algorithm. Poor-quality images, unusual lesions, incomplete histories and differences in skin tone may affect performance. False positives can cause anxiety and unnecessary testing, while false negatives can create false reassurance. Clinicians must be able to challenge or override an AI recommendation.

A Possible NHS Pathway

A general AI-supported pathway could involve:

1. A patient notices a suspicious change or receives a referral.
2. Images and relevant clinical information are collected.
3. AI supports risk assessment or referral prioritisation.
4. A clinician reviews the case and the AI output.
5. The patient receives monitoring, further imaging, a biopsy or treatment.

The exact process may vary between services. Specialist review should consider the patient’s age, medical history, previous skin cancer, family history, sun exposure, symptoms and the lesion’s development over time.

AI used for initial lesion detection is not necessarily the same as AI used for cancer staging or treatment planning. The available reports do not suggest that the Bradford system makes treatment decisions.

Bradford’s Wider Use of Analytics

Bradford Teaching Hospitals has also been linked with plans to expand its “wall of analytics” through a new command centre. The initiative is intended to support operational oversight, capacity planning, waiting-list monitoring and service performance management. Source 7

This hospital-wide analytics initiative is separate from the skin cancer AI project. It may help identify bottlenecks in referrals, appointments, imaging, biopsies and follow-up care, but the available sources do not establish that it directly caused the reported reduction in waiting times.

Benefits and Limitations

Potential benefits include:

• Earlier identification of suspicious lesions.
• Faster triage and specialist review.
• Fewer unnecessary biopsies.
• Better use of dermatology and pathology capacity.
• More consistent support for clinicians.
• Improved visibility of service pressures.

Important limitations include false-positive and false-negative results, difficulty recognising rare cancers, unclear images, incomplete clinical information and unequal performance across demographic groups. Results may vary according to skin tone, lesion type, age, medical history and image quality.

A full evaluation should report sensitivity, specificity, false-positive and false-negative rates, performance across demographic groups, changes in biopsy rates, waiting times at each pathway stage, patient safety outcomes, workload effects and independent clinical or regulatory assessment.

Safety, Privacy and Trust

Clinicians should retain responsibility for diagnosis and treatment decisions. AI-supported decisions should be documented, including how the technology was used and why the final decision was made.

Skin images and medical records are sensitive personal data. Any system handling them requires secure storage, controlled access and clear rules for collection, transfer, retention and use. Patients should receive understandable information about when AI is involved and what it can and cannot do.

Trust depends on validated performance, fair treatment, clear accountability and timely access to a human professional.

Conclusion

Reports indicate that AI technology has helped reduce Bradford’s skin cancer waiting times and the number of dermatology biopsies. Potential benefits include faster assessment, earlier detection, fewer unnecessary procedures and better use of NHS resources. Source 1

The available summaries do not provide detailed performance data, system specifications, full project results or long-term patient outcomes. AI is most effective when combined with expert clinical judgement, validated technology, strong safeguards and timely access to healthcare professionals.

Frequently Asked Questions

Can AI diagnose skin cancer in Bradford?

The reported technology supports clinicians with skin cancer detection and assessment. It should not be treated as an independent replacement for a dermatologist or pathology testing.

How can AI reduce waiting times?

AI may review images, prioritise higher-risk cases and support faster clinical decisions. Its impact depends on staffing, appointment capacity, image quality, pathology services and integration into NHS pathways.

Will AI reduce skin cancer biopsies?

One report links AI with fewer dermatology biopsies. This may reduce unnecessary procedures and pathology demand, but suspicious lesions may still require biopsy. Clinicians must make the final decision.

Is AI skin cancer screening safe?

Safety depends on validated performance, clinical oversight and appropriate governance. Risks include false positives, false negatives, poor-quality images, unusual lesions and unequal performance across skin types.

Will Bradford’s AI project replace dermatologists?

No. The technology is intended to support assessment, triage and service efficiency. Healthcare professionals remain responsible for interpreting results, arranging biopsies and deciding treatment.

What evidence is available?

The supplied reports describe reduced waiting times, fewer biopsies and a project focused on earlier skin cancer detection. They do not provide detailed accuracy statistics, patient outcome data, system specifications or full independent evaluation. Confirmed results should be obtained from Bradford Teaching Hospitals NHS Foundation Trust, NHS publications and independent clinical research.